MedTrace Logo

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT03650491 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-07-27

No results posted yet for this study

Summary

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma.

The name of the study drug involved in this study is: FOR46 for Injection

Conditions

  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Multiple Myeloma With Failed Remission

Interventions

DRUG

FOR46

FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Sponsors & Collaborators

  • Fortis Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrew Dorr, MD · Fortis Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2022-01-31
Completion
2022-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03650491 on ClinicalTrials.gov